Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific transaction rather than a financial performance report.
Material Changes
There were no material changes to the company's financial position reported. The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan, resulting in an increase in the notional allocation of Ordinary share ADRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R (1)(c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on September 30, 2011, with notification on October 3, 2011.
- Parties Involved: The transaction involved Director Dr. M. M. Slaoui and Connected Person Dr. K. Slaoui.
- Transaction Details: An increase of 3 Ordinary share ADRs was recorded at a price of $41.29 per ADR.
- Context: The change resulted from a re-valuation of the cash element of the notional investment within the US Retirement Savings Plan.